Robert J. McKallip

Robert J. McKallip

Auto-generated profile, based on publicly available information

Robert J. McKallip

Division of Biomedical Sciences, Mercer University School of Medicine, Macon, Georgia, United States of America

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in Life Sciences
Verified
Journal Article
Closed access
FBFeng Bai
Feng Bai
XPXue-Fen Pang
Xue-Fen Pang
LZLihui Zhang
Lihui Zhang
NWNing-Ping Wang
Ning-Ping Wang
RMRobert J. McKallip
Robert J. McKallip
ZZZhiqing Zhao
Zhiqing Zhao

24 May 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GBGretchen L. Bentz
Gretchen L. Bentz
ALAngela J. Lowrey
Angela J. Lowrey
DHDustin C. Horne
Dustin C. Horne
VNVy Nguyen
Vy Nguyen
ASAustin R. Satterfield
Austin R. Satterfield
RMRobert J. McKallip
Robert J. McKallip
Cellular sumoylation processes are proposed targets for anti-viral and anti-cancer therapies. We reported that Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) dysregulates cellular sumoylation processes, contributing to its oncogenic potential in EBV-associated malignancies. Ginkgolic acid and anacardic acid, known inhibitors of sumoylation, inhibit LMP1-induced protein sumoylation; however, both drugs have adverse effects in hosts. Here we test the effects of glycyrrhizic acid, a medicinal botanical extract with anti-inflammatory, anti-carcinogenic, and anti-viral properties, on cellular sumoylation processes. While glycyrrhizic acid is known to inhibit EBV penetration, its affect on cellular sumoylation processes remains to be documented. We hypothesized that glycyrrhizic acid inhibits cellular sumoylation processes and may be a viable treatment for Epstein-Barr virus-associated malignancies. Results showed that glycyrrhizic acid inhibited sumoylation processes (without affecting ubiquitination processes), limited cell growth, and induced apoptosis in multiple cell lines. Similar to ginkgolic acid; glycyrrhizic acid targeted the first step of the sumoylation process and resulted in low levels of spontaneous EBV reactivation. Glycyrrhizic acid did not affect induced reactivation of the virus, but the presence of the extract did reduce the ability of the produced virus to infect additional cells. Therefore, we propose that glycyrrhizic acid may be a potential therapeutic drug to augment the treatment of EBV-associated lymphoid malignancies.

1 June 1996 in Glycoconjugate Journal
Verified
Journal Article
Closed access
PDF file
RLRuixiang Li
Ruixiang Li
DGDouglas Gage
Douglas Gage
RMRobert Mckallip
Robert Mckallip
SLStephan Ladisch
Stephan Ladisch

1 June 2020 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
XPXue-Fen Pang
Xue-Fen Pang
LZLi-Hui Zhang
Li-Hui Zhang
FBFeng Bai
Feng Bai
NWNing-Ping Wang
Ning-Ping Wang
RGRon E Garner
Ron E Garner
ZZZhiqing Zhao
Zhiqing Zhao
Attenuation of Myocardial Fibrosis with Curcumin Is Mediated by Modulating Expression of Angiotensin II AT1/AT2 Receptors and ACE2 in Rats [Corrigendum]